These platforms could for instance influence the design of therapeutic antibodies that rely on FcγR or FcεRI engagement, potentially leading to more effective therapies for cancer, immune disorders, and neurodegenerative diseases, or novel vaccines. The gene discussed is FCGR2A; the disease is neurodegenerative disease.